Levetiracetam sustained release tablet drug composition and quality control and preparation method thereof

A levetiracetam acid, slow-release tablet technology is applied in the field of levetiracetam sustained-release tablet pharmaceutical composition and its quality control and preparation method, which can solve the problem of large amount of levetiracetam and cannot be tableted. Satisfactory results have been achieved in the control of the growth rate of piracetam acid impurities, and the coating layer is prone to cracks and other problems

Active Publication Date: 2017-09-15
HUNAN DONGTING PHARMA
View PDF10 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0019] It has been found that the above-mentioned prior art solutions cannot achieve satisfactory results in the improvement of tablet hardness and the control of the growth rate of levetiracetam acid impurities
In addition, due to the excellent water solubility of levetiracetam, the solubility in water is as high as 1.04g / ml, and the proportion of the main component in the tablet is too large (usually greater than 50%), in this case, the erodible type is used. Hydrophilic gel matrix materials such as hypromellose are preferred as sustained-release materials. However, it has been found that tablets prepared with water-soluble excipients and water-soluble main ingredients are prone to cracks in the coating layer after experiencing high temperature and high humidity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Levetiracetam sustained release tablet drug composition and quality control and preparation method thereof
  • Levetiracetam sustained release tablet drug composition and quality control and preparation method thereof
  • Levetiracetam sustained release tablet drug composition and quality control and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0134] Embodiment 1: the preparation of levetiracetam sustained-release tablet

[0135] Tablet prescription:

[0136]

[0137] Preparation method: (1) making levetiracetam pre-crushed into a powder that can pass through a 100-mesh sieve, and making the rest of the materials pre-crushed into a powder that can pass through an 80-mesh sieve;

[0138] (2) Mix levetiracetam with the diluent and a part of the sustained-release framework material (the weight ratio of the part of the sustained-release framework material to the diluent is 0.75:1), spray in a fluidized state Enter 90% ethanol solution (its consumption is 4% of fluidized solid material weight) to make this mixed material bond into granule, make it seal and place 24 hours;

[0139] (3) Continue to fluidize to remove the ethanol solution (to the extent that the water content of the particles drops below 2%), then extrude the resulting material into a block through an extruder, and then crush the powder so that it can p...

Embodiment 2

[0144] Embodiment 2: the preparation of levetiracetam sustained-release tablet

[0145] Tablet prescription:

[0146] Levetiracetam

500mg,

Maltitol

50mg,

Hypromellose K4M

170mg,

Magnesium stearate

4 mg,

Micropowder silica gel

2 mg;

[0147] Preparation method: (1) making levetiracetam pre-crushed into a powder that can pass through a 100-mesh sieve, and making the rest of the materials pre-crushed into a powder that can pass through an 80-mesh sieve;

[0148] (2) Mix levetiracetam with the diluent and a part of the sustained-release matrix material (the weight ratio of the part of the sustained-release matrix material to the diluent is 0.5:1), and spray in a fluidized state Enter 85% ethanol solution (its consumption is 6% of fluidized solid material weight) to make this mixed material bond into granule, make it seal and place 24 hours;

[0149] (3) Continue to fluidize to remove the ethanol solution (to the ext...

Embodiment 3

[0154] Embodiment 3: the preparation of levetiracetam sustained-release tablet

[0155] Tablet prescription:

[0156] Levetiracetam

500mg,

Maltitol

30mg,

Hypromellose K4M+K100M (5:1)

220mg,

Magnesium stearate

2 mg,

Micropowder silica gel

4 mg;

[0157] Preparation method: (1) making levetiracetam pre-crushed into a powder that can pass through a 100-mesh sieve, and making the rest of the materials pre-crushed into a powder that can pass through an 80-mesh sieve;

[0158] (2) Mix levetiracetam with the diluent and a part of the sustained-release matrix material (the weight ratio of the part of the sustained-release matrix material to the diluent is 1:1), and spray it in a fluidized state. Enter 88% ethanol solution (its consumption is 3% of fluidized solid material weight) and make this mixed material bond into granule, make it seal and place 24 hours;

[0159] (3) Continue to fluidize to remove the ethanol solut...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Viscosityaaaaaaaaaa
Viscosityaaaaaaaaaa
Viscosityaaaaaaaaaa
Login to view more

Abstract

The invention relates to a levetiracetam sustained release tablet drug composition and quality control and preparation method thereof, in particular to a method for detecting the quality of a levetiracetam sustained release tablet. The method comprises the following steps: determining the content of active component levetiracetam in the levetiracetam sustained release tablet and the content of impurity levetiracetam acid by utilizing a high-performance liquid phase chromatography, wherein the levetiracetam sustained release tablet is formed by a tablet core and a thin-film coating layer covering the surface of the tablet core, and the tablet core comprises levetiracetam, a sustained release skeleton material, a sustained release agent, a flow aid and a lubricating agent. The invention also relates to a pharmaceutical application of the levetiracetam sustained release tablet. The medicinal composition has good pharmaceutical characteristics and can be used for treating or preventing epilepsy, Parkinson disease, dyskinesia, migraine, tremor, essential tremor, bipolar disorder, chronic pain, neuropathic pain, or bronchus, asthma or allergic diseases.

Description

technical field [0001] The invention relates to a novel pharmaceutical composition containing levetiracetam sustained-release tablets, a quality control method and a preparation method thereof. The levetiracetam sustained-release tablet prepared by the invention has excellent properties. Background technique [0002] European patent EP0162036B discloses a kind of levorotatory compound levetiracetam (Levetiracetam), and its chemical name is (S)-(-)-[α]-ethyl-2-oxo-1-pyrrolidineacetamide, ( -)-(S)-α-ethyl-2-oxo-1-pyrrolidine acetamide. Molecular formula C8H14N2O2, molecular weight 170.21, its chemical structure is as follows: [0003] [0004] Levetiracetam is white to off-white crystalline powder, which is easily soluble in water (1.04g / mL), chloroform (653mg / mL) and methanol (536mg / mL), dissolved in ethanol (165mg / mL), slightly Soluble in acetonitrile (57mg / mL). [0005] Levetiracetam is a cholinergic agonist. The drug is very effective in animal models of epileptic ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N11/14G01N30/02G01N30/06A61K9/36A61K9/30A61K47/38A61K47/26A61K31/4015A61P25/08A61P25/16A61P25/14A61P25/24A61P25/18A61P25/22A61P25/06A61P25/02A61P25/00A61P9/10A61P9/06A61P21/02A61P7/04A61P11/06A61P11/00A61P37/08A61P11/02A61P21/00
CPCA61K9/0002A61K9/2018A61K9/2054A61K9/2853A61K9/2866A61K31/4015G01N11/14G01N30/02G01N30/06
Inventor 侯奇伟谢亮王波郭杰李晓云
Owner HUNAN DONGTING PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap